Plain-English translation of NCT03607422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic dermatitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial examined whether , a daily pill, could help teenagers and adults with moderate to severe eczema (atopic dermatitis) that wasn't controlled by other treatments. Participants received either the medication at one of two doses or a placebo, and researchers tracked how well the treatment worked and how safe it was over several years.
Many people with severe eczema don't get enough relief from topical creams or other existing treatments, and their skin condition significantly impacts their quality of life. This trial was designed to see whether this medication could offer a new treatment option for these patients.
Participants went through a 35-day screening period to confirm they were eligible, then were randomly assigned to receive either the medication or a placebo as a daily pill for 16 weeks. Those who received placebo were then switched to one of the medication doses for up to 260 weeks. Throughout the trial, participants attended visits to have their skin examined and answer questions about their symptoms and how they were doing.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States